Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...
Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...